TISSIUM Secures €60 Million, Accelerates U.S. Market Entry with Innovative Biomorphic Polymers
June 30, 2026, 3:59 pm
TISSIUM secures €60 million in crucial financing. This capital propels global commercial and clinical expansion. The MedTech innovator launches its FDA-approved COAPTIUM CONNECT in the vital U.S. market. It champions a breakthrough biomorphic polymer platform. This technology redefines atraumatic tissue repair for nerves, hernias, and cardiovascular applications. TISSIUM transitions strategically into a commercial-stage entity. The comprehensive funding package combines a €30 million Series D2 equity round with a €30 million European Investment Bank venture debt facility. This investment strongly supports ongoing clinical trials and robust pipeline development. TISSIUM’s proprietary polymers offer novel solutions. They promise enhanced patient recovery and reduced surgical trauma. This marks a transformative period, solidifying its position in advanced medical technology.
TISSIUM, a pioneering MedTech company, recently announced a significant €60 million financing package. This substantial capital infusion will accelerate the company's commercial expansion. It supports extensive clinical activities. It also fuels the development of its product pipeline. Further, it allows for platform expansion. This strategic funding positions TISSIUM for global growth.
The financing comprises two key components. A €30 million Series D2 equity financing round concluded in late 2025. This round drew participation from a diverse group of international investors. New U.S.-based institutional investors joined the existing shareholder base. New family offices and high-net-worth individuals also contributed. Existing investors, including Mérieux Développement and Cathay, reaffirmed their commitment. TISSIUM has now raised a total of €200 million in equity funding. This strengthens its financial foundation.
An additional financing facility of up to €30 million comes from the European Investment Bank (EIB). This venture debt aligns with InvestEU objectives. InvestEU supports research, innovation, and transformative healthcare technologies across Europe. The EIB facility offers strategic flexibility. It is structured in three €10 million tranches. Each tranche links to specific commercial, clinical, and financing milestones. The first tranche is expected before June 2026. This combined package offers robust capital for immediate and future needs.
This financing follows a pivotal period for TISSIUM. The company achieved FDA marketing authorization for COAPTIUM CONNECT. This marks a critical milestone. COAPTIUM CONNECT is TISSIUM’s first commercial product. Its approval enables the company’s entry into the U.S. market. This is a significant strategic move.
TISSIUM specializes in biomorphic programmable polymers. These advanced materials revolutionize tissue reconstruction. The company's platform utilizes fully biosynthetic, biomorphic, programmable, and elastomeric polymers. They address critical unmet needs in atraumatic tissue repair and reconstruction. These polymers act as an adhesive. They bind tissues together. This circumvents the need for traditional invasive stitches. The technology reduces trauma to surrounding tissues. It promises improved patient recovery rates.
The company's pipeline includes one commercial product and six products under development. These target three core areas. The first is atraumatic sutureless nerve repair. The second focuses on atraumatic hernia repair. The third involves cardiovascular sealants. COAPTIUM CONNECT specifically addresses nerve repair challenges. The company also develops solutions for heart defects and hernia treatment. Two of its products, one for nerve repair and one for hernia treatment, have received FDA approval. This underscores the technology's potential.
TISSIUM was founded in 2013. Its origins trace back to groundbreaking research. This intellectual property emerged from Professor Robert Langer’s laboratories at MIT. It also stems from Professor Jeffrey M. Karp’s work at Brigham and Women’s Hospital. The company is headquartered in Paris, France. It also maintains a significant presence in Cambridge, Massachusetts. A manufacturing site operates in Roncq, France. This dual presence facilitates global operations.
The company is now executing a strategic transition. It is moving into a commercial-stage MedTech entity. This involves the commercial rollout of COAPTIUM CONNECT in the United States. It also includes advancing multiple clinical programs. These span various surgical applications. Furthermore, TISSIUM continues to expand its proprietary biomorphic polymer platform. This platform represents a differentiated asset. It drives future innovation.
This financing underscores strong confidence in TISSIUM’s technology. It validates the company’s strategy. It reflects belief in its capacity to deliver meaningful innovation to patients. The capital provides strategic flexibility. It accelerates commercial execution. It also enables continued investment in the platform's future growth. TISSIUM aims to expand its technology into other healthcare areas. This involves funding new clinical trials.
TISSIUM's advancements hold immense promise for patient care. By reducing surgical trauma, their technology offers a less invasive alternative. Faster recovery times improve patient outcomes. The global demand for advanced medical solutions remains high. TISSIUM’s innovative approach positions it as a leader in regenerative medicine. Its biomorphic polymers represent a significant leap forward in tissue engineering. The company is set to redefine surgical repair across multiple medical specialties.
TISSIUM, a pioneering MedTech company, recently announced a significant €60 million financing package. This substantial capital infusion will accelerate the company's commercial expansion. It supports extensive clinical activities. It also fuels the development of its product pipeline. Further, it allows for platform expansion. This strategic funding positions TISSIUM for global growth.
The financing comprises two key components. A €30 million Series D2 equity financing round concluded in late 2025. This round drew participation from a diverse group of international investors. New U.S.-based institutional investors joined the existing shareholder base. New family offices and high-net-worth individuals also contributed. Existing investors, including Mérieux Développement and Cathay, reaffirmed their commitment. TISSIUM has now raised a total of €200 million in equity funding. This strengthens its financial foundation.
An additional financing facility of up to €30 million comes from the European Investment Bank (EIB). This venture debt aligns with InvestEU objectives. InvestEU supports research, innovation, and transformative healthcare technologies across Europe. The EIB facility offers strategic flexibility. It is structured in three €10 million tranches. Each tranche links to specific commercial, clinical, and financing milestones. The first tranche is expected before June 2026. This combined package offers robust capital for immediate and future needs.
This financing follows a pivotal period for TISSIUM. The company achieved FDA marketing authorization for COAPTIUM CONNECT. This marks a critical milestone. COAPTIUM CONNECT is TISSIUM’s first commercial product. Its approval enables the company’s entry into the U.S. market. This is a significant strategic move.
TISSIUM specializes in biomorphic programmable polymers. These advanced materials revolutionize tissue reconstruction. The company's platform utilizes fully biosynthetic, biomorphic, programmable, and elastomeric polymers. They address critical unmet needs in atraumatic tissue repair and reconstruction. These polymers act as an adhesive. They bind tissues together. This circumvents the need for traditional invasive stitches. The technology reduces trauma to surrounding tissues. It promises improved patient recovery rates.
The company's pipeline includes one commercial product and six products under development. These target three core areas. The first is atraumatic sutureless nerve repair. The second focuses on atraumatic hernia repair. The third involves cardiovascular sealants. COAPTIUM CONNECT specifically addresses nerve repair challenges. The company also develops solutions for heart defects and hernia treatment. Two of its products, one for nerve repair and one for hernia treatment, have received FDA approval. This underscores the technology's potential.
TISSIUM was founded in 2013. Its origins trace back to groundbreaking research. This intellectual property emerged from Professor Robert Langer’s laboratories at MIT. It also stems from Professor Jeffrey M. Karp’s work at Brigham and Women’s Hospital. The company is headquartered in Paris, France. It also maintains a significant presence in Cambridge, Massachusetts. A manufacturing site operates in Roncq, France. This dual presence facilitates global operations.
The company is now executing a strategic transition. It is moving into a commercial-stage MedTech entity. This involves the commercial rollout of COAPTIUM CONNECT in the United States. It also includes advancing multiple clinical programs. These span various surgical applications. Furthermore, TISSIUM continues to expand its proprietary biomorphic polymer platform. This platform represents a differentiated asset. It drives future innovation.
This financing underscores strong confidence in TISSIUM’s technology. It validates the company’s strategy. It reflects belief in its capacity to deliver meaningful innovation to patients. The capital provides strategic flexibility. It accelerates commercial execution. It also enables continued investment in the platform's future growth. TISSIUM aims to expand its technology into other healthcare areas. This involves funding new clinical trials.
TISSIUM's advancements hold immense promise for patient care. By reducing surgical trauma, their technology offers a less invasive alternative. Faster recovery times improve patient outcomes. The global demand for advanced medical solutions remains high. TISSIUM’s innovative approach positions it as a leader in regenerative medicine. Its biomorphic polymers represent a significant leap forward in tissue engineering. The company is set to redefine surgical repair across multiple medical specialties.